title: Antihypertensive efficacy and safety of the angiotensin receptor blocker azilsartan in elderly patients with hypertension.
abstract: OBJECTIVE
  The number of elderly patients with hypertension has been steadily increasing. However, there are limited data on the safety and efficacy of the new angiotensin type 1 receptor blocker (ARB) azilsartan in elderly patients with hypertension. We investigated the clinical efficacy and safety of azilsartan in this population.
  
  
  METHODS
  The study population comprised 56 ambulatory patients with essential hypertension. We evaluated the reduction in blood pressure and safety after 12 weeks of treatment with azilsartan in 29 hypertensive patients ≥65 years of age (aged group) in comparison with the findings in 27 patients <65 years of age (non-aged group).
  
  
  RESULTS
  Systolic blood pressure in the aged group declined significantly from 155 ± 18 mmHg at baseline to 138 ± 11 mmHg after 12 weeks of treatment with azilsartan, and that in the non-aged group also declined significantly from 152 ± 20 mmHg at baseline to 142 ± 13 mmHg after 12 weeks of treatment with azilsartan. There were no significant differences in the magnitude of change in blood pressures from pre-treatment to post-treatment with azilsartan between the non-aged and aged groups. There were no changes in clinical laboratory findings, including serum levels of creatinine, potassium, lipids, and other metabolic variables, after 12 weeks of treatment with azilsartan in both groups.
  
  
  CONCLUSIONS
  Our findings suggest that azilsartan is effective in lowering blood pressure in elderly patients and may be safe. Therefore, azilsartan could be a valuable option for treating hypertension in elderly and non-elderly patients.
authors.affiliation: a Department of Cardiology , Fujita Health University, Banbuntane Hotokukai Hospital , Nagoya , Japan and.|b Department of Cardiology , Fujita Health University , Toyoake , Japan.
authors.forename: Tomohito
authors.initials: T
authors.lastname: Kamada
authors.affiliation: a Department of Cardiology , Fujita Health University, Banbuntane Hotokukai Hospital , Nagoya , Japan and.
authors.forename: Mutsuharu
authors.initials: M
authors.lastname: Hayashi
authors.affiliation: a Department of Cardiology , Fujita Health University, Banbuntane Hotokukai Hospital , Nagoya , Japan and.
authors.forename: Wakaya
authors.initials: W
authors.lastname: Fujiwara
authors.affiliation: a Department of Cardiology , Fujita Health University, Banbuntane Hotokukai Hospital , Nagoya , Japan and.
authors.forename: Daiji
authors.initials: D
authors.lastname: Yoshikawa
authors.affiliation: a Department of Cardiology , Fujita Health University, Banbuntane Hotokukai Hospital , Nagoya , Japan and.
authors.forename: Daisuke
authors.initials: D
authors.lastname: Mukaide
authors.affiliation: a Department of Cardiology , Fujita Health University, Banbuntane Hotokukai Hospital , Nagoya , Japan and.
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Sugishita
authors.affiliation: a Department of Cardiology , Fujita Health University, Banbuntane Hotokukai Hospital , Nagoya , Japan and.
authors.forename: Masataka
authors.initials: M
authors.lastname: Yoshinaga
authors.affiliation: a Department of Cardiology , Fujita Health University, Banbuntane Hotokukai Hospital , Nagoya , Japan and.
authors.forename: Takehiro
authors.initials: T
authors.lastname: Itoh
authors.affiliation: a Department of Cardiology , Fujita Health University, Banbuntane Hotokukai Hospital , Nagoya , Japan and.
authors.forename: Hiroatsu
authors.initials: H
authors.lastname: Yokoi
authors.affiliation: b Department of Cardiology , Fujita Health University , Toyoake , Japan.
authors.forename: Junichi
authors.initials: J
authors.lastname: Ishii
authors.affiliation: b Department of Cardiology , Fujita Health University , Toyoake , Japan.
authors.forename: Eiichi
authors.initials: E
authors.lastname: Watanabe
authors.affiliation: b Department of Cardiology , Fujita Health University , Toyoake , Japan.
authors.forename: Yukio
authors.initials: Y
authors.lastname: Ozaki
authors.affiliation: a Department of Cardiology , Fujita Health University, Banbuntane Hotokukai Hospital , Nagoya , Japan and.
authors.forename: Hideo
authors.initials: H
authors.lastname: Izawa
mesh_terms: D000368:Aged; D000553:Ambulatory Care; D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000378:metabolism; D007668:Kidney / Q000187:drug effects; D007677:Kidney Function Tests; D008297:Male; D010069:Oxadiazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D010069:Oxadiazoles; C521273:azilsartan
keywords: Angiotensin type 1 receptor blocker; elderly; hypertension; safety